MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics, based in Zug, Switzerland, is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases. Their primary investigational product, Sonelokimab, is a Nanobody undergoing Phase II trials for conditions like hidradenitis suppurativa, psoriatic arthritis, and ankylosing spondylitis. The company was founded in 2021.
Company Info
Highlights
$3.34B
-$1.27
$39.48K
-$34.48K
-$108.45M
$37.55 - $64.98
$73.92
30.76%
34.43
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in MoonLake Immunotherapeutics, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
MoonLake Immunotherapeutics had a return of -13.48% year-to-date (YTD) and -12.51% in the last 12 months.
MLTX
-13.48%
7.64%
32.31%
-12.51%
N/A
N/A
^GSPC (Benchmark)
23.11%
-0.36%
7.02%
23.15%
12.80%
11.01%
Monthly Returns
The table below presents the monthly returns of MLTX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -7.47% | -13.67% | 4.13% | -18.55% | -0.61% | 8.14% | -5.28% | 12.34% | 7.76% | -7.93% | 17.26% | -13.48% | |
| 2023 | 13.81% | 60.59% | 11.46% | -0.42% | 27.75% | 87.43% | 19.24% | -5.33% | -0.99% | -9.11% | -15.25% | 37.53% | 475.14% |
| 2022 | -0.20% | 0.81% | 11.56% | -44.14% | 24.68% | -32.08% | 20.00% | 27.94% | -3.72% | 6.19% | 20.51% | 5.74% | 6.17% |
| 2021 | -3.25% | 0.00% | -7.27% | -0.88% | -1.09% | 3.50% | -4.17% | -0.38% | 0.71% | 0.50% | -0.70% | -0.40% | -13.02% |
| 2020 | -2.19% | 1.36% | 9.33% | 8.39% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of MLTX is 34, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for MoonLake Immunotherapeutics (MLTX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the MoonLake Immunotherapeutics. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the MoonLake Immunotherapeutics was 64.60%, occurring on May 16, 2022. Recovery took 183 trading sessions.
The current MoonLake Immunotherapeutics drawdown is 18.18%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -64.6% | Apr 6, 2022 | 28 | May 16, 2022 | 183 | Feb 7, 2023 | 211 |
| -41.8% | Oct 6, 2023 | 22 | Nov 6, 2023 | 35 | Dec 27, 2023 | 57 |
| -39.82% | Feb 13, 2024 | 90 | Jun 21, 2024 | — | — | — |
| -25.65% | Feb 19, 2021 | 279 | Mar 28, 2022 | 6 | Apr 5, 2022 | 285 |
| -19.79% | Mar 9, 2023 | 19 | Apr 4, 2023 | 13 | Apr 24, 2023 | 32 |
Volatility
Volatility Chart
The current MoonLake Immunotherapeutics volatility is 16.77%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for MoonLake Immunotherapeutics.
Loading data...
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |